ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
12/23/2025 11:45 PM • The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered by Alvotech's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, following the news. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
ALVO - The company issued materially misleading information regarding its FDA application status. The FDA's complete response letter citing manufacturing deficiencies resulted in a 34% stock price decline, triggering a securities class action investigation for investor losses.